Optimum-UV Clinical & Laboratory Evidence

Similar documents
CAVICIDE1. Technical Bulletin

SYMMETRY FOAMING HAND SANITIZER with Aloe & Vitamin E Technical Data

Antimicrobial Copper Touch Surfaces: A new tool for Infection Control and Prevention

1/30/ Division of Disease Control and Health Protection. Division of Disease Control and Health Protection

Clorox Germicidal Wipes & Spray. The Easy & Most Effective Way to Disinfect

Cleaning and Disinfection Protocol Vegetative Bacteria

Preventing Multi-Drug Resistant Organism (MDRO) Infections. For National Patient Safety Goal

Multi-Drug Resistant Organisms (MDRO)

SYMMETRY ANTIMICROBIAL FOAMING HANDWASH with 0.3% PCMX Technical Data

Cleaning and Disinfection Protocol for Gram-Negative and Gram-Positive Bacteria, including Antibiotic Resistant Bacteria

Horizontal vs Vertical Infection Control Strategies

MICRO-ORGANISMS by COMPANY PROFILE

Infection Prevention Highlights for the Medical Staff. Pamela Rohrbach MSN, RN, CIC Director of Infection Prevention

Taking Action to Prevent and Manage Multidrug-resistant Organisms and C. difficile in the Nursing Home: Part 1 Reviewing the organisms

Antibiotic Resistance. Antibiotic Resistance: A Growing Concern. Antibiotic resistance is not new 3/21/2011

New and Innovative Applications for Metals COPPER. Tony Lea International Copper Association

METRIGUARD. Technical Bulletin

What bugs are keeping YOU up at night?

Risk of organism acquisition from prior room occupants: A systematic review and meta analysis

Other Enterobacteriaceae

Vaccination as a potential strategy to combat Antimicrobial Resistance in the elderly

Summary of the latest data on antibiotic resistance in the European Union

Is biocide resistance already a clinical problem?

Test Method Modified Association of Analytical Communities Test Method Modified Germicidal Spray Products as Disinfectants

Guidelines for Laboratory Verification of Performance of the FilmArray BCID System

11/22/2016. Hospital-acquired Infections Update Disclosures. Outline. No conflicts of interest to disclose. Hot topics:

Overview of Infection Control and Prevention

Preventing and Responding to Antibiotic Resistant Infections in New Hampshire

BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016)

3 Infection Prevention Solutions

Presented by: Mary McGoldrick, MS, RN, CRNI

03/09/2014. Infection Prevention and Control A Foundation Course. Talk outline

Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs?

TECHNICAL BULLETIN PURELL Advanced with Aloe Instant Hand Sanitizer

Hand Hygiene and MDRO (Multidrug-resistant Organisms) - Science and Myth PROF MARGARET IP DEPT OF MICROBIOLOGY

Cleaning & Sanitising Medical range. Working in harmony with nature to protect

9/30/2016. Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS

The International Collaborative Conference in Clinical Microbiology & Infectious Diseases

Control of Multidrug-resistant Organisms in a Hospital Environment: Multidimensional Approach

17June2017. Parampal Deol, Ph.D, MBA Senior Director, R&D Microbiology North America

Two (II) Upon signature

Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities.

INFECTION PREVENTION SILVER ANTI-MICROBIAL TEXTILES

Infection Linelist. Infections Occurred Between 10/1/ :00:00 AM To 11/1/ :00:00 AM 2RCW2. Gastroenteritis (Adult) Urinary Tract

The Disinfecting Effect of Electrolyzed Water Produced by GEN-X-3. Laboratory of Diagnostic Medicine, College of Medicine, Soonchunhyang University

Liofilchem Chromatic Chromogenic culture media for microbial identification and for the screening of antimicrobial resistance mechanisms

Infection Control of Emerging Diseases

Concise Antibiogram Toolkit Background

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Activity C: ELC Prevention Collaboratives

Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them?

4 th and 5 th generation cephalosporins. Naderi HR Associate professor of Infectious Diseases

Antimicrobial stewardship: Quick, don t just do something! Stand there!

Antibiotics in the future tense: The Application of Antibiotic Stewardship in Veterinary Medicine. Mike Apley Kansas State University

Appropriate antimicrobial therapy in HAP: What does this mean?

Antibiotic stewardship in long term care

MDRO s, Stewardship and Beyond. Linda R. Greene RN, MPS, CIC

No-leaching. No-resistance. No-toxicity. >99.999% Introducing BIOGUARD. Best-in-class dressings for your infection control program

HEALTHCARE-ACQUIRED INFECTIONS AND ANTIMICROBIAL RESISTANCE

Objectives. Basic Microbiology. Patient related. Environment related. Organism related 10/12/2017

11/22/2016. Antimicrobial Stewardship Update Disclosures. Outline. No conflicts of interest to disclose

Antibiotic Stewardship Program (ASP) CHRISTUS SETX

THE STATE OF THE STATE: ANTIBIOTIC RESISTANCE AND STEWARDSHIP

Surveillance of Multi-Drug Resistant Organisms

The Hospital Environment as a Source of Resistant Gram Negatives

Multidrug Resistant Organisms (MDROs) and Clostridium difficile (C. diff)

RCH antibiotic susceptibility data

CUMULATIVE ANTIBIOGRAM

Aberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015

Problem: Hospital Acquired Infections

Antimicrobial Stewardship:

TABLE OF CONTENTS. 1. Purpose of the WRHA Infection Prevention and Control Manual 2.1 and approval process

Antimicrobial Resistance. The Case for Diagnostics to Better Direct Therapy

SURVIVABILITY OF HIGH RISK, MULTIRESISTANT BACTERIA ON COTTON TREATED WITH COMMERCIALLY AVAILABLE ANTIMICROBIAL AGENTS

Get Smart For Healthcare

Cipro for gram positive cocci in urine

Antibiotic Stewardship in Nursing Homes SAM GUREVITZ PHARM D, CGP ASSOCIATE PROFESSOR BUTLER UNIVERSITY COLLEGE OF PHARMACY AND HEALTH SCIENCE

Medline Micro-Kill and Medline Micro-Kill+ Hard-Surface Germicidal Wipes Now With and Without Alcohol!

ANTIMICROBIAL STEWARDSHIP IN LONG TERM CARE FACILITIES

C&W Three-Year Cumulative Antibiogram January 2013 December 2015

28/08/2017. Infection Prevention and Control. Safe Patient Care Bugs and Drugs The ongoing challenge of MDROs and AMR

(DRAFT) RECOMMENDATIONS FOR THE CONTROL OF MULTI-DRUG RESISTANT GRAM-NEGATIVES: CARBAPENEM RESISTANT ENTEROBACTERIACEAE

Human health impacts of antibiotic use in animal agriculture

: "INFECTION CONTROL: WHAT'S COMING IN 2017?" LISA THOMAS RN-BC STATE TRAINING COORDINATOR OFFICE OF LONG TERM CARE

MDRO in LTCF: Forming Networks to Control the Problem

New Drugs for Bad Bugs- Statewide Antibiogram

The Cost of Antibiotic Resistance: What Every Healthcare Executive Should Know

AMR epidemiological situation: ECDC update

Original Articles. K A M S W Gunarathne 1, M Akbar 2, K Karunarathne 3, JRS de Silva 4. Sri Lanka Journal of Child Health, 2011; 40(4):

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016

APIC CHAPTER PRESENTATION 7/2014

Public Health Response to Emerging Resistance

Birgit Ross Hospital Hygiene University Hospital Essen Essen, Germany. Should we screen for multiresistant gramnegative Bacteria?

Surveillance of Antimicrobial Resistance and Healthcare-associated Infections in Europe

Infection Control Manual Residential Care Part 3 Infection Control Standards IC7: 0100 Methicillin Resistant Staphylococcus aureus

Antibiotic Stewardship in the LTC Setting

VCU study suggests antimicrobial scrubs may reduce bacteria May also help decrease risk of MRSA transmission to patients

New Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs

2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose

Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland

2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose

Transcription:

Optimum-UV Clinical & Laboratory Evidence safeguarding patient environments

TABLE OF CONTENTS Laboratory Micro-Efficacy Testing Proven against more than 30 HAI-causing pathogens in 5 minutes at 8 feet... 3 Clinical Evidence St. Mary s Hospital for Children Marianne Pavia, MS, BS, CIC, FAPIC... 5 The Optimum-UV System was associated with a 44% reduction in viral infection incidence among pediatric patients in a long-term care facility. University of Pennsylvania David Pegues, MD... 7 The Optimum-UV System reduced C. difficile infection (CDI) rates by 25% and averted $134,568 $191,604 annual direct medical costs in Hematology/Oncology units. University of Iowa Hospitals and Clinics Vincent Masse, MD... 9 The Optimum-UV Enlight System kills C. difficile and MRSA with shorter cycle times and at a lower cost than the Tru-D UV-C device. Johns Hopkins Hospital Lisa Maragakis, MD, MPH... 11 The Optimum-UV System achieved a >5 log reduction against carbapenem-resistant Enterobacteriaceae (CRE; K. pneumoniae, E. coli and E. cloacae) in patient rooms. Cleveland Clinic Abhishek Deshpande, MD, PhD and Curtis Donskey, MD... 13 Optimum-UV System effectively reduced the presence of multidrug-resistant organisms (MDROs), including C. difficile and methicillin-resistant Staphylococcus aureus (MRSA) in patient rooms. Louis Stokes Cleveland VA Medical Center Curtis Donskey, MD...15 The Optimum-UV System effectively kills C. difficile and methicillin-resistant Staphylococcus aureus (MRSA); standardized UV-C device efficacy testing is needed so that different devices can be compared. UNC Health Care William Rutala, MS, MPH, PhD... 17 The Optimum-UV System is effective against carbapenem-resistant Enterobacteriaceae (CRE) and methicillin-resistant Staphylococcus aureus (MRSA) plated on Formica laminate in patient rooms. UNC Health Care William Rutala, MS, MPH, PhD... 19 The Optimum-UV System is effective against methicillin-resistant Staphylococcus aureus (MRSA) and C. difficile plated on Formica laminate in patient rooms. University of Arizona Charles Gerba, PhD... 21 The Optimum-UV System effectively inactivates C. difficile spores, MS-2 virus and MRSA on long-term care fomites when used in conjunction with Clorox Healthcare Hydrogen Peroxide. OASIS Hospital Maurice Croteau... 23 A simple test demonstrates effective microbial load reduction by the Optimum-UV System in an acute care setting when tested on vertical, horizontal and chemical sensitive surfaces. Women s Hospital, Deaconess Health System Sonya Mauzey, RN, BS, CIC...25 The Optimum-UV System reduces Pseudomonas aeruginosa infection incidence among patients in a neonatal intensive care unit. Clinical studies and posters are also available digitally at https://www.cloroxprofessional.com/products/clorox-healthcare-optimum-uv-system/literature/ The studies enclosed are presented for informational purposes only. Please consult your Clorox Healthcare account representative for any questions. 2

KILLS more than Including: 30 HAI-causing pathogens in 5 minutes at 8 feet. 4-log reduction of C. difficile spores Greater than 5-log reduction of over 20 pathogens, including MRSA, VRE and CRE 3

Performance Validated by Third-Party Laboratory Micro-Efficacy Testing Testing Distance and Time: 8 feet, 5 minutes 4.0 Log Reduction 5.0 Log Reduction 6.0 Log Reduction Fungi Candida albicans Bacterial Spores Clostridium difficile Viruses Adenovirus Hepatitis A Virus Hepatitis C Virus Herpes Simplex Virus 2 Human Coronavirus Respiratory Syncytial Virus Rhinovirus Rotavirus Ebola Virus Enterovirus 68 Herpes Simplex Virus 1 Influenza A Virus (H1N1) Middle East Respiratory Syndrome Coronavirus (MERS CoV) Norovirus Poliovirus Bacteria Acinetobacter baumannii Bordetella pertussis Escherichia coli Escherichia coli (carbapenemresistant; CRE) Enterococcus faecium (vancomycinresistant; VRE) Listeria monocytogenes Methicillin-resistant Staphylococcus aureus (MRSA) Mycobacterium bovis (TB surrogate) Pseudomonas aeruginosa Salmonella enterica Staphylococcus aureus Staphylococcus epidermis (coagulasenegative; CoNS) Enterobacter aerogenes Enterococcus faecalis Klebsiella pneumoniae Proteus mirabilis Serratia marcescens Via bovine viral diarrhea virus surrogate Via feline calicivirus surrogate 4

St. Mary s Hospital for Children The Optimum-UV System was associated with a 44% reduction in viral infection incidence among pediatric patients in a long-term care facility. Principal Investigator: Marianne Pavia, MS, BS, CIC, FAPIC, St. Mary s Hospital for Children Purpose: To examine the impact of the Optimum-UV System on viral infection incidence in a long-term care pediatric facility. Methods: The Optimum-UV System was included as an adjunct to standard cleaning protocols for 13 months in a long-term care pediatric facility. UV-C disinfection was focused on the toddler unit, where HAI rates were highest at the time of the intervention. Treatment included patient rooms as well as common areas. Viral respiratory infections were identified using reverse transcription PCR and incidence data were collected in an electronic medical record and tracked monthly throughout the course of the study. Results: Comparing viral infection incidence rates for the 13-month UV-C deployment period with infection incidence rates for the prior 13-month period, a 44% unadjusted reduction in overall viral infection incidence was found (P-value=0.003), corresponding to an Incidence Rate Ratio [IRR] of 0.56 (95% Confidence Interval [CI]: 0.37-0.84). Patient days per month remained approximately constant throughout the study period, and no other new interventions were implemented during the study period, suggesting that the decrease in viral infection incidence was due solely to the addition of UV-C. References: Pavia, Marianne; Simpser, Edwin; Becker, Melissa; Mainquist, W. Keith; Velez, K. A. The Impact of Ultraviolet-C Technology on Viral Infection Incidence in a Pediatric Long Term Care Facility. Am. J. Infect. 2018, in press. 5

University of Pennsylvania The Optimum-UV System reduced C. difficile infection (CDI) rates by 25% and averted $134,568 $191,604 annual direct medical costs in Hematology/Oncology units. Principal Investigator: David Pegues, MD, Professor of Medicine, Hospital of the University of Pennsylvania Purpose: To examine the impact of Optimum-UV System deployment combined with manual surface disinfection with bleach on C. difficile infection rates in Hematology/Oncology units over a 12-month evaluation period. Methods: The Optimum-UV System was deployed for a 12-month intervention period, in combination with standard manual surface disinfection with bleach. CDI rates were tracked pre- and post-intervention. Results: Deployment of the Optimum-UV System resulted in a 25% decrease in CDI rates on the study units, as compared to the baseline period. An estimated $134,568 to $191,604 in annual direct medical costs were averted by preventing 21 cases of CDI on the study units. Baseline (Jan. 2013 Dec. 2013) Intervention (Feb. 2014 Jan. 2015) CDI Rate* 30.34 22.85 *CDI rate is per 10,000 patient day References: Pegues, D.A.; Han, J.; Gilmar, C.; McDonnell, B.; Gaynes, S. Impact of Ultraviolet Germicidal Irradiation for No-Touch Terminal Room Disinfection on Clostridium Difficile Infection Incidence Among Hematology-Oncology Patients. Infect. Control Hosp. Epidemiol. 2016 Pegues, D.; Gilmar, C.; Denno, M.; Gaynes, S. Reducing Clostridium difficile Infection among Hematology-Oncology Patients Using Ultraviolet Germicidal Irradiation for Terminal Room Disinfection. In IDWeek (poster presentation); 2015. 7

University of Iowa Hospitals and Clinics The Optimum-UV Enlight System kills C. difficile and MRSA with shorter cycle times and at a lower cost than the Tru-D UV-C device. Principal Investigator: Vincent Masse, MD, University of Iowa Carver College of Medicine and University of Iowa Hospitals and Clinics Purpose: To compare the performance of several UV surface disinfection devices, including the Optimum-UV Enlight System and Tru-D. Methods: UV-C system output was compared using a radiometer, at a set of fixed times and distances. Output in a patient room was also compared using a radiometer and Clorox Healthcare Dose Verify cards to detect dose delivery to surfaces when following the directions for use recommended by each manufacturer (i.e., single placement in a room for Tru-D, and multiple placements for the Optimum-UV Enlight System). Results: The authors reported that both the Optimum-UV Enlight System and Tru-D devices delivered more than enough UV-C to surfaces 5, 8, and 10 feet away from the device to kill C. difficile and MRSA within a 5 minute cycle time. The authors also demonstrated that multiple device placements with shorter cycle times, which Clorox recommends, are preferred over the single placement with longer cycle times that Tru-D recommends, based on dose delivered to a variety of hospital room surfaces. They noted that an additional cycle in the bathroom, which Clorox recommends, is required for adequate UV-C delivery in bathrooms and other adjoining rooms. Tru-D s single placement in the main room failed to deliver sufficient UV-C to adjoining bathrooms to kill C. difficile or MRSA. References: Masse, V.; Hartley, M. J.; Edmond, M. B.; Diekema, D. J. Comparing and Optimizing Ultraviolet Germicidal Irradiation Systems Use for Patient Room Terminal Disinfection: An Exploratory Study Using Radiometry and Commercial Test Cards. 2018, 7 (1), 29. 9

Johns Hopkins Hospital The Optimum-UV System achieved a >5 log reduction against carbapenem-resistant Enterobacteriaceae (CRE; K. pneumoniae, E. coli, and E. cloacae) in patient rooms. Principal Investigator: Lisa Maragakis, MD, MPH, Senior Director of Infection Prevention and Associate Professor of Medicine, The Johns Hopkins Health System Purpose: To examine Optimum-UV System efficacy against carbapenem-resistant Enterobacteriaceae (CRE; K. pneumoniae, E. coli and E. cloacae) plated on Formica. This study is part of a cluster, randomized, two-period crossover trial focused on evaluating MDRO transmission that includes daily patient room cleaning with UV-C in addition to terminal cleaning in Oncology and Solid Organ Transplant units. Methods: UV-C was applied to carbapenem-resistant Enterobacteriaceae plated on Formica placed on more than 17 high-touch surfaces in a patient room and bathroom. Results: The Optimum-UV System achieved a >5 log reduction against all three CRE microorganisms tested. No CRE microorganisms grew on 131 out of 133 plates tested following three 5-minute cycles of exposure to UV-C. References: Rock, C.; Curless, M.S.; Nowakowski, E.; Ross, T.; Carson, K.A.; Trexler, P.; Carroll, K.; Maragakis, L.L. UV-C Light Disinfection of Carbapenem-Resistant Enterobacteriaceae from High-Touch Surfaces in a Patient Room and Bathroom. Infect. Control Hosp. Epidemiol. 2016, 1 2. Rock, C.; Curless, M.; Nowakowski, E.; Ross, T.; Carson, K.; Trexler, P.; Carroll, K.; Maragakis, L. UV Light Decontamination of Carbapenem-Resistant Enterobacteriaceae from High Touch Surfaces in a Patient Room and Bathroom. In SHEA (poster presentation); 2016. 11

Cleveland Clinic Optimum-UV System effectively reduced the presence of multidrugresistant organisms (MDROs), including C. difficile and methicillin-resistant Staphylococcus aureus (MRSA) in patient rooms. Principal Investigators: Abhishek Deshpande, MD, PhD, Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine at Case Western Reserve University Curtis Donskey, MD, Professor of Medicine, Case Western Reserve University and Staff Physician, Infectious Diseases Section, Louis Stokes Cleveland VA Medical Center Purpose: To examine Optimum-UV System effectiveness against nosocomial pathogens in hospital rooms, including C. difficile and methicillin-resistant Staphylococcus aureus (MRSA). This study is part of a randomized ward-level crossover study on four medical surgical wards during an 8-month period, focused on evaluating C. difficile infection (CDI) rates. This study also included an evaluation of healthcare worker and environmental services staff perceptions. Methods: The Optimum-UV System was run in isolation rooms on two units in an acute-tertiary care hospital for 6 months. Each patient room was treated for two 5-minute cycles, and the patient bathroom for one 5-minute cycle, for a total of 15 minutes per room. Cultures were collected before and after UV-C treatment to determine the levels of contamination of C. difficile, MRSA, vancomycin-resistant Enterococcus (VRE), and multidrug-resistant gram-negative organisms. Results: The Optimum-UV System achieved significant reduction in recovery of MRSA and C. difficile during the intervention period, as compared to the preintervention period. MRSA and C. difficile recovery was reduced by 76% (p=0.03) during the intervention, as compared to the preintervention period. References: Deshpande, A.; Hartley, J.; Cadnum, J.; Jencson, A.; Sankar, T. Effectiveness of an Ultraviolet Light Decontamination Device in Reducing Hospital Room Contamination. In SHEA (poster presentation); 2016; p. 549. Deshpande, A.; Hartley, J.; Einloth, C.; Fatica, C.; Donskey, C.; Fraser, T. Perceptions of Healthcare Workers and Environmental Services Staff Regarding Ultraviolet Room Decontamination Devices. In APIC (poster presentation); 2016; p. 251. 13

Louis Stokes Cleveland VA Medical Center The Optimum-UV System effectively kills C. difficile and methicillinresistant Staphylococcus aureus (MRSA); standardized UV-C device efficacy testing is needed so that different devices can be compared. Principal Investigator: Curtis Donskey, MD, Professor of Medicine, Case Western Reserve University and Staff Physician, Infectious Diseases Section, Louis Stokes Cleveland VA Medical Center Purpose: To determine the impact of variation in UV-C efficacy test methods on log reduction results. Methods: Two UV-C devices, including the Optimum-UV System, were compared using a single test method for efficacy against MRSA and C. difficile. The Optimum-UV System was then subjected to further testing whereby one variable at a time was altered to assess the impact on the results, including carrier distance from the lamps, height of the carriers relative to the floor, carrier type, inoculum spread, carrier angle relative to the device and organic load. Results: A >3 log reduction was achieved within 5 minutes for MRSA for both UV devices tested. As expected, log reductions for MRSA and C. difficile changed, depending on the variables tested, including inoculum dispersal, organic load, carrier orientation and carrier height. This study demonstrates the need for industrywide standards for evaluating UV-C device efficacy. References: Cadnum, J.L.; Tomas, M.E.; Sankar, T.; Jencson, A.; Mathew, J.I.; Kundrapu, S.; Donskey, C.J. Effect of Variation in Test Methods on Performance of Ultraviolet-C Radiation Room Decontamination. Infect. Control Hosp. Epidemiol. 2016, 1 6. Cadnum, J.L.; Mana, T.S.C.; Jencson, A.L.; Deshpande, A.; Donskey, C.J. Not All Efficacy Testing Is Created Equal: Effect of Variation in Test Methods on Performance of an Ultraviolet Radiation Room Disinfection Device. In SHEA (poster presentation); 2015. 15

UNC Health Care The Optimum-UV System is effective against carbapenem-resistant Enterobacteriaceae (CRE) and methicillin-resistant Staphylococcus aureus (MRSA) plated on Formica laminate in patient rooms. Principal Investigator: William Rutala, MS, MPH, PhD, Director of Hospital Epidemiology, UNC School of Medicine Purpose: To examine Optimum-UV System efficacy against methicillin-resistant Staphylococcus aureus (MRSA) and carbapenem-resistant Klebsiella pneumoniae (CRKP) plated on Formica, using two different device placement methods. Methods: UV-C was applied to clinical isolates of MRSA and carbapenem-resistant Klebsiella pneumoniae (CRKP) plated on Formica laminate placed at various locations in a patient room. Two separate experiments were run using two different UV device placement setups to compare the log reductions obtained with each setup. In setup A, the device was placed in the center of the room and run for a single 5-minute cycle, and in setup B, the device was run for two 5-minute cycles with the device placed on either side of the patient bed. Results: The Optimum-UV System achieved a >5 log reduction for directly exposed sites and a >4 log reduction for indirectly exposed sites against MRSA and CRKP in 10 minutes. Setup A was comparable to Setup B, with a statistically significant improvement in log reduction found for Setup B. This difference may not be clinically relevant, however, as a >2 log reduction is proposed to be clinically effective by the study authors. Pathogen MRSA CRKP Device Setup Setup A (one cycle) Setup B (two cycles) Setup A (one cycle) Setup B (two cycles) Surface Type (Log 10 Reduction) (Log 10 Reduction) Direct Surfaces 5.27 5.82 5.74 6.61 Indirect Surfaces 4.17 4.55 4.53 5.39 Overall 4.61 5.06 5.01 5.87 Reference: Kanamori, H.; Rutala, W.A.; Gergen, M.F.; Weber, D.J. Patient Room Decontamination against Carbapenem-Resistant Enterobacteriaceae and Methicillin-Resistant Staphylococcus aureus Using a Fixed Cycle-Time Ultraviolet-C Device and Two Different Radiation Designs. Infect. Control Hosp. Epidemiol. 2016, 1 3. 17

UNC Health Care The Optimum-UV System is effective against methicillin-resistant Staphylococcus aureus (MRSA) and C. difficile plated on Formica laminate in patient rooms. Principal Investigator: William Rutala, MS, MPH, PhD, Director of Hospital Epidemiology, UNC School of Medicine Purpose: To examine Optimum-UV System efficacy against methicillin-resistant Staphylococcus aureus (MRSA) and C. difficile spores plated on Formica. Methods: UV-C was applied to MRSA and C. difficile spores plated on Formica laminate placed at various locations in two patient rooms. The UV device was run for either a single 5-minute cycle, or a 10-minute cycle to simulate the recommended two 5-minute cycle times to treat a patient room. Results: The Optimum-UV System achieved a 3.56 log reduction against methicillin-resistant Staphylococcus aureus (MRSA) in 5 minutes, and a 2.78 log reduction against C. difficile spores in 10 minutes. Pathogen MRSA (5 minutes) C. difficile spores (10 minutes) Surface Type (Log 10 Reduction) Direct Surfaces 4.1 3.35 Indirect Surfaces 2.74 1.8 Overall 3.56 2.78 Reference: Rutala, W.A.; Gergen, M.F.; Tande, B.M.; Weber, D.J. Room Decontamination Using an Ultraviolet-C Device with Short Ultraviolet Exposure Time. Infect. Control Hosp. Epidemiol. 2014, 35, 1070 1072. 19

University of Arizona The Optimum-UV System effectively inactivates C. difficile spores, MS-2 virus and MRSA on long-term care fomites when used in conjunction with Clorox Healthcare Hydrogen Peroxide. Principal Investigator: Charles Gerba, PhD, Professor, Microbiology & Environmental Sciences, University of Arizona Purpose: To examine the effectiveness of the Optimum-UV System combined with Clorox Healthcare Hydrogen Peroxide against C. difficile spores, MS-2 virus and MRSA. Methods: C. difficile spores, MS-2 virus and MRSA were plated on stainless steel, and MRSA was additionally plated on Formica and 100% polyester. Then each plate was treated with Clorox Healthcare Hydrogen Peroxide, followed by 10 minutes of exposure to the Optimum-UV System. Results: Hydrogen peroxide, when used in conjunction with UV, resulted in a 4.0 log reduction against MRSA, C. difficile spores and MS-2 virus. This treatment effectively removed >6.0 logs of MRSA from the soft surface polyester. Pathogen MRSA (10 minutes) C. difficile spores (10 minutes) MS-2 virus (10 minutes) Surface Type (Log 10 Reduction) Stainless Steel 4.14 >4 8.2 Formica >5.3 -- -- Polyester >6.0 -- -- Reference: Sifuentes, L.Y.; Peterson, A.; Pivo, T.; Gerba, C.P. Ultra Violet Light Efficacy in the Absence of Cleaning. In APIC (poster presentation); 2015. 21

OASIS Hospital A simple test demonstrates effective microbial load reduction by the Optimum-UV System in an acute care setting when tested on vertical, horizontal and chemical-sensitive surfaces. Principal Investigator: Maurice Croteau, Director of Healthcare Services, Western Paper Distributors Purpose: To demonstrate the effectiveness of a simple test method to evaluate microbial load reduction in hospital rooms following treatment with UV-C. Methods: High-touch surfaces were sampled before and after UV-C treatment using RODAC contact plates. More than 30 surface types were tested in operating rooms, burn units, intensive care units and a special procedures unit in two hospitals. Results: A simple, easy-to-use microbial test showed that the Optimum-UV System significantly reduced microbial presence on a variety of surfaces in two hospitals following standard manual surface disinfection. UV-C was effective on all surface types tested, including vertical, horizontal and sensitive electronic surfaces. Reference: Croteau, M.E.; Grover, T.M. Evaluating the Efficacy of UV-C Technology in Acute Care. In APIC (poster presentation); 2015. 23

Women s Hospital Deaconess Health System The Optimum-UV System reduces Pseudomonas aeruginosa infection incidence among patients in a neonatal intensive care unit. Principal Investigator: Sonya Mauzey, RN, BS, CIC, Infection Preventionist, The Women s Hospital Deaconess Health System Purpose: To examine the impact of Optimum-UV on Pseudomonas aeruginosa infection incidence in a neonatal intensive care unit. Methods: A retrospective review of positive Pseudomonas aeruginosa culture incidence was conducted on patients in a neonatal intensive care unit for a period of 3 years. Manual surface disinfection alone was used in the first half of the study (1.5 years), and the Optimum-UV System was used as an adjunct to manual surface disinfection during the second half of the study. Results: Only one positive Pseudomonas aeruginosa culture was found among neonatal intensive care unit patients in the 1.5-year period when the Optimum-UV System was used, as compared to 32 positive cultures found in the 1.5-year baseline period when manual surface disinfection alone was used. Reference: Mauzey, S. Impact of Ultraviolet Technology on Incidence of Pseudomonas in a Neonatal Intensive Care Unit. In APIC (poster presentation); 2015. 25

safeguarding patient environments For more information, contact your Clorox Healthcare sales representative. Call 800-234-7700, email: uv@clorox.com or visit us: www.cloroxhealthcare.com 2018 Clorox Professional Products Company, 1221 Broadway, Oakland, CA 94612. NI-42189